MarketScale Announces the Return of DisruptED

 

MarketScale is excited to announce the return of podcast series DisruptED with hosts Ron Stefanski and Caesar Mickens Jr., Ph.D starting Tuesday April 12th, 2022.

“DisruptED” is a podcast that understands the reality we live in. Thoughtful, riveting, and uplifting, the show centers on the disruption caused by the pandemic, technology, and globalization in education.

In this age of “The Great Resignation,” employees are quitting their jobs to find upward movement in a market that is trying to find skills that don’t exist yet. How do we manage this? Where do we go from here? Who is leading whom?

Co-hosts Ron Stefanski, who is a career educator and workforce development leader in the private and public sector and has spent his entire career in the education field and Dr. Caesar Mickens, who is a specialist in adult education and professional development and has led public-private partnerships to increased access to educational opportunities for at-risk youth and adults, have extensive knowledge in and around the education system today, allowing them to inform expertise throughout the podcast series.

The premier episode brings on guest Karin Norington-Reaves, a leader in workforce development to talk about her success in blending private and public entities and giving opportunity back to the workforce.

The guest list for the season also includes David Lawrence and Jeffrey Mims Jr. and their roles in helping youth in education, Smart Horizons Career Education Online Kari Greenfield and Dr. Howard Liebman, COO of Automation Alley Pavan Muzumdar, and Liberty Educational Service Center’s Tom Kelly.

To get to the bottom of disruption and find out what’s next for the future of education and workforce development, tune in to the new episode of DisruptED April 12th here.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More